D. E. Shaw & Co., Inc. Amylyx Pharmaceuticals, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AMLX
# of Institutions
140Shares Held
44.6MCall Options Held
226KPut Options Held
909K-
Vanguard Group Inc Valley Forge, PA4.22MShares$13 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.34MShares$10.3 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$8.22 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.61MShares$8.04 Million0.0% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.9MShares$5.86 Million1.57% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $180M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...